Open AccessTargeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation
Author(s) -
Fang Yang,
Shaogang Sun,
Chenran Wang,
Michael Haas,
Syn Kok Yeo,
JunLin Guan
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0839-1
Subject(s) - mtorc1 , cancer research , autophagy , histone deacetylase , cancer cell , biology , programmed cell death , apoptosis , cell growth , cancer , pi3k/akt/mtor pathway , microbiology and biotechnology , signal transduction , biochemistry , histone , genetics , gene
The mechanistic target of rapamycin complex 1 (mTORC1) is important in the development and progression of many cancers. Targeted cancer therapy using mTORC1 inhibitors is used for treatment of cancers; however, their clinical efficacies are still limited.